

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568488
Filing Date	2006-02-14
First Named Inventor	Monia
Art Unit	1635
Examiner Name	To Be Determined Terra C. Gibbs
Attorney Docket Number	ISPH-0859USA

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5801154		1998-09-01	Baracchini et al.	
	2	6140124		2000-10-31	Monia et al.	
	3	6448079		2002-09-10	Monia et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030176383	A1	2003-09-18	Monia et al.	
	2	20040171566	A1	2004-09-02	Monia et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
-------------------	---------	--------------------------------------	---------------------------	------------------------	------------------	-------------------------------------------------	--------------------------------------------------------------------------	----------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568488
Filing Date		2006-02-14
First Named Inventor	Monia	
Art Unit	1635	
Examiner Name	To Be Determined Terra C. Gibbs	
Attorney Docket Number	ISPH-0859USA	

1	9835978	WO	A1	1998-08-20	Isis Pharmaceuticals	<input type="checkbox"/>
2	9960166	WO	A1	1999-11-25	Isis Pharmaceuticals	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" Molecular Medicine Today (2000) 6:72-81.	<input type="checkbox"/>
	2	AOSHIBA, K. et al., "Role of p38-Mitogen-Activated Protein Kinase in Spontaneous Apoptosis of Human Neutrophils," J. Immunol. (1999) 162:1692-1700.	<input type="checkbox"/>
	3	ARIMA, H. et al., "Specific Inhibition of Nitric Oxide Production in Macrophages by Phosphorothioate Antisense Oligonucleotides," J. Pharm. Sci. (1997) 86(10):1079-1084.	<input type="checkbox"/>
	4	BRANCH, A. D., "A good antisense molecule is hard to find," TIBS (1998) 23:45-50.	<input type="checkbox"/>
	5	CHIALDA, L. et al., "Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia," Respiratory Research (2005) 6:36.	<input type="checkbox"/>
	6	COHEN, P. S. et al., "The Critical Role of p38 MAP Kinase in T Cell HIV-1 Replication," Molecular Medicine (1997) 3 (5):339-346.	<input type="checkbox"/>
	7	CROOKE, S. T., "Basic Principles of Antisense Therapeutics," Antisense Research and Application (1998) Springer-Verlag, New York, pp. 1-50.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10568488
Filing Date	2006-02-14
First Named Inventor	Monia
Art Unit	1635
Examiner Name	To Be Determined Terra C. Gibbs
Attorney Docket Number	ISPH-0859USA

8	DATABASE EMBL:HS1206359 "zv26e08.s1 Soares_NhHMPu_S1 Homo sapiens cDNA clone IMAG:754790 3' similar to TR:G1304132 G1304132 TPRD., mRNA sequence," 4 May 1997 XP002302626 retrieved from EBI accession no. EM_EST:1206359 Database accession no. HS1206359.	<input type="checkbox"/>
9	DUAN, W. et al., "Inhaled p38 Mitogen-Activated Protein Kinase Antisense Oligonucleotides Attenuates Asthma in Mice," Am. J. Respir. Crit. Care Med. (2005) 171:571-578.	<input type="checkbox"/>
10	GREEN, D. W. et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease," J. Am. Coll. Surg. (2000) 191:93-105.	<input type="checkbox"/>
11	HAN, J. et al., "A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells," Science (1994) 265:808-811.	<input type="checkbox"/>
12	JEN, K.-Y. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells (2000) 18:307-319.	<input type="checkbox"/>
13	KUMAR, R. K. et al., "Murine Model of Chronic Human Asthma," Immunology and Cell Biology (2001) 79:141-144.	<input type="checkbox"/>
14	NAGATA, Y. et al., "Activation of p38 MAP Kinase and JNK But Not ERK Is Required for Erythropoietin-Induced Erythroid Differentiation," Blood (1998) 92(6):1859-1869.	<input type="checkbox"/>
15	NICK, J. A. et al., "Role of p38 Mitogen-Activated Protein Kinase in a Murine Model of Pulmonary Inflammation," J. Immunol. (2000) 164:2151-2159.	<input type="checkbox"/>
16	NYCE, J. W., "Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases," Expert. Opin. Investig. Drugs (1997) 6(9):1149-1156.	<input type="checkbox"/>
17	NYCE, J. W. et al., "DNA antisense therapy for asthma in an animal model," Nature (1997) 385(6618):721-725.	<input type="checkbox"/>
18	RICHARDS, I. M., "Mouse models of allergic disease; how do they relate to asthma in man?" Clinical and Experimental Allergy (1996) 26:618-620.	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10568488
Filing Date		2006-02-14
First Named Inventor	Monia	
Art Unit	1635	
Examiner Name	To Be Determined	Terra C. Gibbs
Attorney Docket Number	ISPH-0859USA	

19	SALE, E. M. et al., "Use of an antisense strategy to dissect the role of MAP kinases in cellular signaling," Biochemical Society Transactions (1998) 26(3):S254.	<input type="checkbox"/>
20	TEMELKOVSKI, J. et al., "An improved murine model of asthma selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen," Thorax (1998) 53:849-856.	<input type="checkbox"/>
21	WONG, W. S. F., "Inhibitors of the tyrosine kinase signaling cascade for asthma," Current Opinion in Pharmacology (2005) 5:264-271.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Terra Cotta Gibbs/	Date Considered	09/12/2008
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/